Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DHTN76
|
|||
| Drug Name |
ALN-CC5
|
|||
| Drug Type |
Antisense oligonucleotide
|
|||
| Indication | Haemolytic uraemic syndrome [ICD-11: 3A21.2; ICD-10: D59.3] | Phase 2 | [1] | |
| Company |
Alnylam Pharmaceuticals: Cemdisiran
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | C5 messenger RNA (C5 mRNA) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03303313) A Study of an Investigational Drug, Cemdisiran (ALN-CC5), in Patients With Atypical Hemolytic Uremic Syndrome. U.S. National Institutes of Health. | |||
| REF 2 | Investigational RNAi Therapeutic Targeting C5 Is Efficacious in Pre-clinical Models of Myasthenia Gravis. Mol Ther Methods Clin Dev. 2019 May 10;13:484-492. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.